lactic acid has been researched along with Parkinson Disease in 27 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Parkinson disease is associated with decreased activity of the mitochondrial electron transport chain." | 1.42 | MicroRNA-7 Promotes Glycolysis to Protect against 1-Methyl-4-phenylpyridinium-induced Cell Death. ( Chaudhuri, AD; Choi, DC; Junn, E; Kabaria, S; Mouradian, MM, 2015) |
| " In this study, we assessed the effects of a subpopulation of human MSCs, the marrow-isolated adult multilineage inducible (MIAMI) cells, combined with pharmacologically active microcarriers (PAMs) in a rat model of Parkinson's disease (PD)." | 1.37 | The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats. ( Delcroix, GJ; Garbayo, E; Montero-Menei, CN; Schiller, PC; Sindji, L; Thomas, O; Vanpouille-Box, C, 2011) |
| "A total of 66 participants with Parkinson's disease and 32 age-matched, healthy controls participated." | 1.32 | Effects of respiratory muscle weakness on daily living function, quality of life, activity levels, and exercise capacity in mild to moderate Parkinson's disease. ( Castle, PC; Haas, BM; Trew, M, 2004) |
| "Patient 2 presented with multiple symmetric lipomatosis." | 1.31 | Mitochondrial DNA rearrangements in young onset parkinsonism: two case reports. ( Bonuccelli, U; Ceravolo, R; Iudice, A; Lombardi, V; Mancuso, M; Siciliano, G, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (11.11) | 18.2507 |
| 2000's | 8 (29.63) | 29.6817 |
| 2010's | 12 (44.44) | 24.3611 |
| 2020's | 4 (14.81) | 2.80 |
| Authors | Studies |
|---|---|
| Fedotova, EI | 1 |
| Dolgacheva, LP | 1 |
| Abramov, AY | 1 |
| Berezhnov, AV | 1 |
| Choi, J | 1 |
| Tak, S | 1 |
| Jung, HM | 1 |
| Cha, S | 1 |
| Hwang, E | 1 |
| Lee, D | 1 |
| Lee, JH | 1 |
| Ryu, KS | 1 |
| Park, C | 1 |
| Coukos, JS | 1 |
| Lee, CW | 1 |
| Pillai, KS | 1 |
| Shah, H | 1 |
| Moellering, RE | 1 |
| Miyaue, N | 1 |
| Yabe, H | 1 |
| Nagai, M | 1 |
| Moradian, H | 1 |
| Keshvari, H | 1 |
| Fasehee, H | 1 |
| Dinarvand, R | 1 |
| Faghihi, S | 1 |
| Barcia, E | 2 |
| Boeva, L | 1 |
| García-García, L | 1 |
| Slowing, K | 2 |
| Fernández-Carballido, A | 2 |
| Casanova, Y | 1 |
| Negro, S | 2 |
| Matsuda, N | 1 |
| Kimura, M | 1 |
| Queliconi, BB | 1 |
| Kojima, W | 1 |
| Mishima, M | 1 |
| Takagi, K | 1 |
| Koyano, F | 1 |
| Yamano, K | 1 |
| Mizushima, T | 1 |
| Ito, Y | 1 |
| Tanaka, K | 1 |
| Xie, CL | 1 |
| Wang, WW | 1 |
| Zhang, SF | 1 |
| Yuan, ML | 1 |
| Che, JY | 1 |
| Gan, J | 1 |
| Song, L | 1 |
| Yuan, WE | 1 |
| Liu, ZG | 1 |
| Chaudhuri, AD | 1 |
| Kabaria, S | 1 |
| Choi, DC | 1 |
| Mouradian, MM | 1 |
| Junn, E | 1 |
| Pahuja, R | 1 |
| Seth, K | 1 |
| Shukla, A | 1 |
| Shukla, RK | 1 |
| Bhatnagar, P | 1 |
| Chauhan, LK | 1 |
| Saxena, PN | 1 |
| Arun, J | 1 |
| Chaudhari, BP | 1 |
| Patel, DK | 1 |
| Singh, SP | 1 |
| Shukla, R | 1 |
| Khanna, VK | 1 |
| Kumar, P | 1 |
| Chaturvedi, RK | 1 |
| Gupta, KC | 1 |
| Tuppy, M | 1 |
| Barna, BF | 1 |
| Alves-Dos-Santos, L | 1 |
| Britto, LR | 1 |
| Chiavegatto, S | 1 |
| Moreira, TS | 1 |
| Takakura, AC | 1 |
| Bourdenx, M | 1 |
| Daniel, J | 1 |
| Genin, E | 1 |
| Soria, FN | 1 |
| Blanchard-Desce, M | 1 |
| Bezard, E | 1 |
| Dehay, B | 1 |
| Yelkenli, İH | 1 |
| Ulupinar, E | 1 |
| Korkmaz, OT | 1 |
| Şener, E | 1 |
| Kuş, G | 1 |
| Filiz, Z | 1 |
| Tunçel, N | 1 |
| Garbayo, E | 2 |
| Montero-Menei, CN | 2 |
| Ansorena, E | 1 |
| Lanciego, JL | 1 |
| Aymerich, MS | 1 |
| Blanco-Prieto, MJ | 1 |
| Delcroix, GJ | 1 |
| Sindji, L | 1 |
| Thomas, O | 1 |
| Vanpouille-Box, C | 1 |
| Schiller, PC | 1 |
| Martins-Branco, D | 1 |
| Esteves, AR | 1 |
| Santos, D | 1 |
| Arduino, DM | 1 |
| Swerdlow, RH | 1 |
| Oliveira, CR | 1 |
| Januario, C | 1 |
| Cardoso, SM | 1 |
| Fernández, M | 1 |
| Garcia, L | 1 |
| Abdo, WF | 1 |
| De Jong, D | 1 |
| Hendriks, JC | 1 |
| Horstink, MW | 2 |
| Kremer, BP | 1 |
| Bloem, BR | 1 |
| Verbeek, MM | 1 |
| Haas, BM | 1 |
| Trew, M | 1 |
| Castle, PC | 1 |
| Dahm, R | 1 |
| Zijlmans, JC | 1 |
| de Koster, A | 1 |
| van 't Hof, MA | 1 |
| Thijssen, HO | 1 |
| Heerschap, A | 1 |
| Moy, LY | 1 |
| Zeevalk, GD | 1 |
| Sonsalla, PK | 1 |
| Gårseth, M | 1 |
| Sonnewald, U | 1 |
| White, LR | 1 |
| Rød, M | 1 |
| Zwart, JA | 1 |
| Nygaard, O | 1 |
| Aasly, J | 1 |
| Matsubara, K | 1 |
| Senda, T | 1 |
| Uezono, T | 1 |
| Awaya, T | 1 |
| Ogawa, S | 1 |
| Chiba, K | 1 |
| Shimizu, K | 1 |
| Hayase, N | 1 |
| Kimura, K | 1 |
| Siciliano, G | 1 |
| Mancuso, M | 1 |
| Ceravolo, R | 1 |
| Lombardi, V | 1 |
| Iudice, A | 1 |
| Bonuccelli, U | 1 |
| Nakagawa-Hattori, Y | 1 |
| Yoshino, H | 1 |
| Kondo, T | 1 |
| Mizuno, Y | 1 |
| Horai, S | 1 |
| Bravi, D | 1 |
| Anderson, JJ | 1 |
| Dagani, F | 1 |
| Davis, TL | 1 |
| Ferrari, R | 1 |
| Gillespie, M | 1 |
| Chase, TN | 1 |
27 other studies available for lactic acid and Parkinson Disease
| Article | Year |
|---|---|
Lactate and Pyruvate Activate Autophagy and Mitophagy that Protect Cells in Toxic Model of Parkinson's Disease.
Topics: Animals; Astrocytes; Autophagy; Cell Line, Tumor; Cell Survival; Humans; Lactic Acid; Membrane Poten | 2022 |
Kinetic evidence in favor of glyoxalase III and against deglycase activity of DJ-1.
Topics: Aldehyde Oxidoreductases; Humans; Lactic Acid; Parkinson Disease; Protein Deglycase DJ-1; Pyruvaldeh | 2023 |
PARK7 Catalyzes Stereospecific Detoxification of Methylglyoxal Consistent with Glyoxalase and Not Deglycase Function.
Topics: Humans; Lactic Acid; Magnesium Oxide; Parkinson Disease; Protein Deglycase DJ-1; Pyruvaldehyde | 2023 |
Serum growth differentiation factor 15, but not lactate, is elevated in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Asian People; Biomarkers; Case-Control Studies; Female; Growth Differentiat | 2020 |
Combining NT3-overexpressing MSCs and PLGA microcarriers for brain tissue engineering: A potential tool for treatment of Parkinson's disease.
Topics: Brain; Cell Differentiation; Humans; Lactic Acid; Mesenchymal Stem Cells; Parkinson Disease; Polygly | 2017 |
Nanotechnology-based drug delivery of ropinirole for Parkinson's disease.
Topics: Animals; Drug Carriers; Drug Delivery Systems; Indoles; Lactic Acid; Male; Nanoparticles; Parkinson | 2017 |
Parkinson's disease-related DJ-1 functions in thiol quality control against aldehyde attack in vitro.
Topics: Acetylcysteine; Aldehydes; Amino Acid Sequence; beta-Alanine; Coenzyme A; Glutathione; HeLa Cells; H | 2017 |
Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
Topics: Adrenergic Agents; Animals; Benserazide; Blotting, Western; Corpus Striatum; Cyclic AMP-Dependent Pr | 2014 |
MicroRNA-7 Promotes Glycolysis to Protect against 1-Methyl-4-phenylpyridinium-induced Cell Death.
Topics: 1-Methyl-4-phenylpyridinium; Adenosine Triphosphate; Animals; Cell Death; Cell Differentiation; Cell | 2015 |
Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats.
Topics: Animals; Blood-Brain Barrier; Cell Line, Tumor; Dopamine; Dopaminergic Neurons; Drug Carriers; Drug | 2015 |
Respiratory deficits in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Cell Count; Corpus Striatum; Disease Models, Animal; Hydrogen-Ion Concen | 2015 |
Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases.
Topics: 1-Methyl-4-phenylpyridinium; Acids; Alkalies; Animals; Cell Death; Dopaminergic Neurons; Humans; Hyd | 2016 |
Modulation of Corpus Striatal Neurochemistry by Astrocytes and Vasoactive Intestinal Peptide (VIP) in Parkinsonian Rats.
Topics: Animals; Astrocytes; Corpus Striatum; gamma-Aminobutyric Acid; Glial Fibrillary Acidic Protein; Glio | 2016 |
Effective GDNF brain delivery using microspheres--a promising strategy for Parkinson's disease.
Topics: Animals; Brain; Cell Differentiation; Corpus Striatum; Disease Models, Animal; Drug Carriers; Drug D | 2009 |
The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats.
Topics: Animals; Behavior, Animal; Cell Differentiation; Female; Fluorescent Antibody Technique; Humans; Lac | 2011 |
Ubiquitin proteasome system in Parkinson's disease: a keeper or a witness?
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Case-Control Studies; Cell Line, | 2012 |
Controlled release of rasagiline mesylate promotes neuroprotection in a rotenone-induced advanced model of Parkinson's disease.
Topics: Animals; Apoptosis; Behavior, Animal; Cell Line, Tumor; Delayed-Action Preparations; Disease Models, | 2012 |
Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease.
Topics: Adult; Aged; Benzamides; Brain; Diagnosis, Differential; Electromyography; Enzyme-Linked Immunosorbe | 2004 |
Effects of respiratory muscle weakness on daily living function, quality of life, activity levels, and exercise capacity in mild to moderate Parkinson's disease.
Topics: Activities of Daily Living; Aged; Exercise; Exercise Test; Exercise Tolerance; Female; Health Status | 2004 |
Dying to see.
Topics: Acquired Immunodeficiency Syndrome; Aged; Aging; Alzheimer Disease; Animals; Apoptosis; Cataract; Ey | 2004 |
Proton magnetic resonance spectroscopy in suspected vascular ischemic parkinsonism.
Topics: Aged; Aspartic Acid; Brain; Brain Ischemia; Brain Mapping; Energy Metabolism; Female; Humans; Intrac | 1994 |
Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures.
Topics: 2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; 3,4-Dihydrox | 2000 |
Proton magnetic resonance spectroscopy of cerebrospinal fluid in neurodegenerative disease: indication of glial energy impairment in Huntington chorea, but not Parkinson disease.
Topics: Adult; Aged; Citric Acid; Energy Metabolism; Female; Humans; Huntington Disease; Lactic Acid; Magnet | 2000 |
L-Deprenyl prevents the cell hypoxia induced by dopaminergic neurotoxins, MPP(+) and beta-carbolinium: a microdialysis study in rats.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Carbolines; Cell Hypoxia; Dopamine; Dose-Response Relationship | 2001 |
Mitochondrial DNA rearrangements in young onset parkinsonism: two case reports.
Topics: Adult; Creatine Kinase; DNA, Mitochondrial; Gene Rearrangement; Humans; Lactic Acid; Lipomatosis, Mu | 2001 |
Is Parkinson's disease a mitochondrial disorder?
Topics: Aerobiosis; Aged; Blotting, Southern; DNA, Mitochondrial; Exercise Test; Humans; Lactates; Lactic Ac | 1992 |
Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.
Topics: Age Factors; Blood Glucose; Blood Platelets; Carbidopa; Drug Therapy, Combination; Energy Metabolism | 1992 |